Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Condition: CD20-positive Non-Hodgkin Lymphoma Intervention: Drug: EX103 injection Sponsor: Guangzhou Excelmab Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials